Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilia Fishbein

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 22, 2022
Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistanceIvan S Alferiev, David T Guerrero, Peng Guan, et al.
Human Gene Therapy|June 28, 2003
The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: in vitro and in vivo feasibility studiesDenise Y Burton, Cunxian Song, Ilia Fishbein, et al.
Atherosclerosis|January 19, 2024
Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptideIlia Fishbein, Vaishali V Inamdar, Ivan S Alferiev, et al.
Acta Biomaterialia|January 15, 2020
Stability and bioactivity of pepCD47 attachment on stainless steel surfacesVaishali V Inamdar, Emmett Fitzpatrick, Ivan Alferiev, et al.
Biomaterials|March 16, 2015
Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapyIvan S Alferiev, Radhika Iyer, Jamie L Croucher, et al.
Scientific Reports|April 1, 2022
Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1Bahman Hooshdaran, Benjamin B Pressly, Ivan S Alferiev, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 24, 2005
Bisphosphonate-mediated gene vector delivery from the metal surfaces of stentsIlia Fishbein, Ivan S Alferiev, Origene Nyanguile, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 22, 2022
Poloxamer-linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high-risk neuroblastoma with primary and acquired chemoresistanceIvan S Alferiev, David T Guerrero, Peng Guan, et al.
Human Gene Therapy|June 28, 2003
The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: in vitro and in vivo feasibility studiesDenise Y Burton, Cunxian Song, Ilia Fishbein, et al.
Atherosclerosis|January 19, 2024
Hypercholesterolemia exacerbates in-stent restenosis in rabbits: Studies of the mitigating effect of stent surface modification with a CD47-derived peptideIlia Fishbein, Vaishali V Inamdar, Ivan S Alferiev, et al.
Acta Biomaterialia|January 15, 2020
Stability and bioactivity of pepCD47 attachment on stainless steel surfacesVaishali V Inamdar, Emmett Fitzpatrick, Ivan Alferiev, et al.
Biomaterials|March 16, 2015
Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapyIvan S Alferiev, Radhika Iyer, Jamie L Croucher, et al.
Scientific Reports|April 1, 2022
Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1Bahman Hooshdaran, Benjamin B Pressly, Ivan S Alferiev, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 24, 2005
Bisphosphonate-mediated gene vector delivery from the metal surfaces of stentsIlia Fishbein, Ivan S Alferiev, Origene Nyanguile, et al.
Pageof 5